Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: A single arm clinical trial

BMC Cancer

Volumn 2, Issue , 2002, Pages

  He, Xing Yue ^a   Elson, Paul ^a   Pohlman, Brad ^a   Lichtin, Alan ^a   Hussein, Mohamad ^a   Andresen, Steve ^a   Kalaycio, Matt ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; KARYOTYPE; KIDNEY FAILURE; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPHIL; OPPORTUNISTIC INFECTION; SEIZURE; SEPSIS; SEQUENTIAL ANALYSIS; TIME; VERTIGO; ACUTE DISEASE; CELL COUNT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPHILS; PLATELET COUNT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042750626     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-12     Document Type: Article

References (47)

1. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86(2):457-462
2. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group [see comments]. New Engl J Med 1995, 332(25):1678-1683
3. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. New Engl J Med 1995, 332(25):1671-1677
4. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998, 91(10):3607-3615
5. Hamblin TJ: Disappointments in treating acute leukemia in the elderly. N Engl J Med 1995, 332(25):1712-1713
6. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996, 88(10):3675-3685
7. Jahns-Streubel G, Reuter C, Unterhalt M, Schleyer E, Wormann B, Buchner T, Hiddemann W: Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia. Leukemia 1995, 9(11):1857-1863
8. Karp JE, Burke PJ, Donehower RC: Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity. Leukemia 1990, 4(8):553-556
9. Liesveld JL, Keng PC, Rowe JM, DiPersio JF, Abboud CN: Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. Leuk Res 1994, 18(8):609-616
10. Smith MA, Smith JG, Pallister CJ, Singer CR: Haemopoietic growth factors the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside. Leuk Lymphoma 1996, 23(5-6):467-472
11. Tanaka M: Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res 1993, 17(7):585-592
12. te Boekhorst PA, Lowenberg B, Sonneveld P: Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994, 8(9):1480-1486
13. te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P: Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF IL-3 or GM-CSF stimulation. Leukemia 1993, 7(8):1191-1198
14. Bernell P, Kimby E, Hast R: Recombinant human granulocytemacrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 1994, 8(10):1631-1639
15. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S: Use of granulocyte colony-stimulating factor before during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994, 12(4):671-678
16. Hansen PB, Johnsen HE, Jensen L, Gaarsdal E, Simonsen K, Ralfkiaer E: Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective randomized pilot study. Eur J Haematol 1995, 54(5):296-303
17. Buchner T, Hiddemann W, Wormann B, Rottmann R, Maschmeyer G, Ludwig WD, Zuhlsdorf M, Buntkirchen K, Sander A, Aswald J: The role of GM-CSF in the treatment of acute myeloid leukemia. Leuk Lymphoma 1993, 11(Suppl 2):21-24
18. Puntous M, Lacombe F, Dumain P, Marit G, Cony-Makhoul P, Belloc F, Boiron JM, Laurent G, Bernard P, Reiffers J: Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. Leuk Lymphoma 1993, 12(1-2):95-102
19. Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P: Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. Cancer Invest 1993, 11(2):229-234
20. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994, 83(8):2086-2092
21. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J: GM-CSF in a double-blind randomized placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995, 9(1):3-9
22. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY, Lioure B, Witz B, Francois S, Desablens B, Pignon B, Le Prise PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL: A placebo-controlled study of recombinant granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998, 91(8):2722-2730
23. Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmur J, Gratwohl A, Hess U, Fey MF, van Putten WL: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997, 15(12):3496-3506
24. Hansen PB, Johnsen HE, Lund JO, Hansen MS, Hansen NE: Unexpected hepatotoxicity after priming and treatment with molgramostim (rhGM-CSF) in acute myeloid leukemia during induction chemotherapy. Am J Hematol 1995, 48(1):48-51
25. Wiley JS, Jamieson GP, Cebon JS, Woodruff RK, McKendrick JJ, Szer J, Gibson J, Sheridan WP, Biggs JC, Rallings MC: Cytokine priming of acute myeloid leukemia may produce a pulmonary syndrome when associated with a rapid increase in peripheral blood myeloblasts [letter]. Blood 1993, 82(11):3511-3512
26. Estey EH: Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994, 83(8):2015-2019
27. Burke PJ, Karp JE, Vaughan WP, Sanford PL: Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy. Blood Cells 1982, 8(3):519-533
28. Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW, Fox MG, Zahurak M, Morrell L, Hall KL: A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989, 74(5):1499-1506
29. Arlin ZA, Kempin SJ, Mertelsmann R, Gee TS, Clarkson B: Patients with secondary acute myelocytic leukemia (AML) receiving "timed" sequential chemotherapy [letter]. J Clin Oncol 1983, 1(8):513
30. Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F, Cony-Makhoul P, Tilly H, Troussard X, Auzanneau G, Thomas X, Ffrench M, Marie JP: Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematol Cell Therapy 1996, 38(2):161-167
31. Kalaycio M: Inpatient managment of acute leukemia. Cleveland Clinic Journal of Medicine 1997, 64(7):385-389
32. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D: Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991, 77(9):1894-1900
33. Tafuri A, Andreeff M: Cell kinetic modulation of hematological malignancies by cytokines: Recruitment therapy to overcome cytokinetic resistance. In: Hematopoietic growth factors in clinical applications (Edited by: Mertelsmann R Herrmann F) New York Marcel Dekker Inc. 1990, 381-399
34. Rowe JM, Neuberg D, Friedenberg W, et al: A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993). Blood 1998, 92(Suppl):Abs 1284
35. Reece DE, Elmongy MB, Barnett MJ, Klingemann HG, Shepherd JD, Phillips GL: Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. Cancer Invest 1993, 11(5):509-516
36. Hiddemann W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Becker K, Balleisen L, Lathan B: High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 1993, 10:133-137
37. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992, 10(7):1103-1111
38. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W: High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 1997, 79(1):59-68
39. Schiller G, Emmanoulides C, Iastrebner M, Lee M, Naeim F: Highdose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Leuk Lymphoma 1996, 20(5-6):427-434
40. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P: Timed sequential chemotherapy for previously treated patients with acute
41. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E: Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999, 13:1214-1220
42. Hoyle CF, de Bastos M, Wheatley K, Sherrington PD, Fischer PJ, Rees JK, Gray R, Hayhoe FG: AML associated with previous cytotoxic therapy MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989, 72(1):45-53
43. Kantarjian HM, Estey EH, Keating MJ: Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin Nor Am 1993, 7(1):81-108
44. Loffler H, Schmitz N, Gassmann W: Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol Oncol Clin Nor Am 1992, 6(3):619-631
45. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH: Improved survival for patients acute myelogenous leukemia. J Clin Oncol 1995, 13(3):560-569
46. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996, 87(12):4979-89
47. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985, 103:626